Ticagrelor and Scopolamine drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Ticagrelor (ticagrelor) and Scopolamine (scopolamine). Common drug interactions include blood triglycerides increased among females and stress cardiomyopathy among males.
The phase IV clinical study analyzes what interactions people have when they take Ticagrelor and Scopolamine. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.
What is Ticagrelor?
Ticagrelor has active ingredients of ticagrelor. eHealthMe is studying from 8,499 Ticagrelor users. Check the latest studies of Ticagrelor.
What is Scopolamine?
Scopolamine has active ingredients of scopolamine. eHealthMe is studying from 4,945 Scopolamine users. Check the latest studies of Scopolamine.
29 people who take Ticagrelor and Scopolamine together, and have interactions are studied.

What are the common drug interactions of Ticagrelor and Scopolamine, by gender? *:
female:
- Blood triglycerides increased
- High density lipoprotein decreased
- Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
- Red cell distribution width increased
- Progressive multiple sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord)
- Vision blurred
- Primary progressive multiple sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged)
male:
- Stress cardiomyopathy (stress-induced chronic disease of the heart muscle)
What are the common drug interactions of Ticagrelor and Scopolamine, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
- Vision blurred
- Stress cardiomyopathy (stress-induced chronic disease of the heart muscle)
40-49:
n/a
50-59:
n/a
60+:
- Blood triglycerides increased
- High density lipoprotein decreased
- Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
- Red cell distribution width increased
- Progressive multiple sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord)
- Primary progressive multiple sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged)
What are the existing conditions these people have? *
- Type 2 Diabetes: 26 people, 89.66%
- Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 26 people, 89.66%
* Approximation only. Some reports may have incomplete information.
Do you take Ticagrelor and Scopolamine?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Ticagrelor (8,499 reports)
- Scopolamine (4,945 reports)
Browse all drug interactions of Ticagrelor and Scopolamine:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Ticagrelor:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Scopolamine:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Ticagrelor and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Scopolamine and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on ticagrelor and scopolamine (the active ingredients of Ticagrelor and Scopolamine, respectively), and Ticagrelor and Scopolamine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Losartan Potassium vs. Exforge, side effect and effectiveness comparison - 3 seconds ago
- Drug interactions of Potassium and Ammonium Chloride - 4 seconds ago
- Chestnut and Dyspnoea for Men aged 60+ - 38 seconds ago
- Chestnut and Dyspnea for Men aged 60+ - 38 seconds ago
- Benlysta and Fibromyalgia Syndrome for Women aged 30-39 - 49 seconds ago
- Benlysta and Myofascial Pain Syndrome for Women aged 30-39 - 50 seconds ago
- Benlysta and Fibrositis for Women aged 30-39 - 50 seconds ago
- Benlysta and Fibromyositis for Women aged 30-39 - 51 seconds ago
- Benlysta and Fibromyalgia for Women aged 30-39 - 51 seconds ago
- Drug interactions of Ocrevus and Darifenacin Hydrobromide - 55 seconds ago